Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a GD3 monoclonal antibody, conferring specific immunity against GD3 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating solid tumors such as melanomas, carcinomas or liquid tumor such as T-cell lymphoblastic leukemia.

Abstract: A chimeric antigen receptor including a co-inhibitory receptor signaling domain, as well as a nucleic acid construct and immune cells expressing the same are described. Kits and methods of using the immune cells in the treatment or amelioration of chronic inflammation or immune-mediated autoimmunity are also provided.

Abstract: Provided in the present invention is a PDL-1 molecule. The affinity of the PDL-1 molecule to the PD-1 molecule is at least two times the affinity of the wild-type PDL-1 molecule to the PD-1 molecule. Meanwhile, the PDL-1 molecule of the present invention can effectively improve the killing efficiency of lymphocytes. In addition, the present invention also provides nucleic acids encoding the PDL-1 molecule of the present invention, and a complex of the PDL-1 molecules of the present invention. The PDL-1 molecule of the present invention may be used alone or in combination with other molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: A plant produced chimeric polypeptide is provided. The plant produced chimeric polypeptide comprising: (i) a first domain which comprises a TNF Alpha binding domain of a TNF receptor, and (ii) a second domain which comprises an Fc domain of an immunoglobulin, wherein the first domain and the second domain are N-terminally to C-terminally respectively sequentially translationally fused and wherein the chimeric polypeptide specifically binds TNF Alpha.

Abstract: Compositions are disclosed that include D-amino acid peptides and that are capable of specifically binding to at least one autoantibody against a G-protein coupled receptor. The autoantibody is produced in a patient having or being predisposed to a disease condition or disorder, and the autoantibody is capable of binding to a specific epitope of the G-protein coupled receptor. Methods of production and use of said compositions are also disclosed.

Abstract: Lipoplex formulations and uses thereof. In particular, the lipoplexes include at least one naturally-occurring cationic amphiphile, at least one C18-30 saturated fatty acid, cholesterol, at least one nucleic acid, and have a low charge ratio. The lipoplexes are useful for in vivo or in vitro delivery of one or more agents (e.g., a polyanionic therapeutic or an antisense therapeutic, such as an RNAi agent) and allow prolonged expression of these agents, which may be distributed via endogenous cellular pathways to surrounding cells or tissue.

Abstract: The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.

Abstract: Neutralizing antibodies and antigen binding fragments that specifically bind to Ebola virus glycoprotein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting Ebola virususing the antibodies and antigen binding fragments are disclosed. The antibodies, antigen binding fragments, nucleic acids, and vectors, can be used, for example, to prevent and/or treat Ebola virusinfection in a subject.

Abstract: CAR cells targeting tumor necrosis therapy relevant antigens are described as a new method of cancer treatment. It is proposed that TNT CAR cells are safe and effective in patients and can be used to treat human tumors and cancer.

Abstract: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.

Abstract: The invention relates to a multiple-variable dose method for treating a disorder in which TNF? activity is detrimental, comprising administering to a subject in need thereof a first induction dose of an anti-TNF? antibody which ranges from 161 to 320 mg such that a threshold level of TNF? inhibitor is achieved within an induction phase; and subsequently administering to the subject at least one treatment dose of the TNF? inhibitor within a treatment phase, such that treatment occurs

Abstract: The invention relates to a multiple-variable dose method for treating a disorder in which TNF? activity is detrimental, comprising administering to a subject in need thereof a first induction dose of an anti-TNF? antibody which ranges from 161 to 320 mg such that a threshold level of TNF? inhibitor is achieved within an induction phase; and subsequently administering to the subject at least one treatment dose of the TNF? inhibitor within a treatment phase, such that treatment occurs

Abstract: Bispecific antibodies are provided that bind Calcitonin Gene Related Peptide (CGRP) and Interleukin-23 (IL-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both CGRP and IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease and Ulcerative Colitis, Psoriatic Arthritis (PsA) and ankylosing spondylitis (AS).

Abstract: Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.

Abstract: Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.

Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Abstract: The present invention relates to method for treating or alleviating the symptoms of peripheral arterial disease (PAD) in a subject, comprising administering about 25 mg to about 300 mg of an IL-1? binding antibody or functional fragment thereof.

Abstract: The disclosure relates to human anti-NRG1 neutralizing monoclonal antibodies that do not interfere with the NRG1 binding to the HER3 receptor and uses thereof. More particularly, an isolated human monoclonal antibody comprising a heavy and light chain variable regions with specific CDRs defined by their sequences is disclosed.

Abstract: Novel antibodies and antigen binding fragments that specifically bind to KAAG1 and which may be used in the treatment, detection and diagnosis of cancer comprising KAAG1-expressing cells are disclosed herein. Cells expressing the antibodies and antigen binding fragments as well as methods of detecting and treating cancer using the antibodies and fragments are also disclosed. Cancer indications which may benefit from such treatment or detection include ovarian cancer, renal cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, and prostate cancer, as well as melanomas.

Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.

Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.

Abstract: The present invention relates to a ligand molecule that specifically binds to KTR3DL2 at the surface of KTR3DL2 expressing malignant T-cells for the treatment of lymphomas. It also relates to the in vitro use of a level of expression of KIR3DL2 is a biomarker useful for diagnosing and/or monitoring a lymphoma.

Abstract: The present invention relates to the field of medical biology, and discloses a single domain antibody and derivative proteins thereof against programmed death ligand (PDL1). In particular, the present invention discloses a programmed death ligand 1 (PDL1) binding molecular and the use thereof, especially the use for treating and/or preventing or diagnosing PDL1 relevant diseases such as tumor.

Abstract: The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies.

Abstract: The present invention provides antibodies that bind to Tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Tie2 and block the interaction between Tie2 and one or more Tie2 ligands such as angiopoietin 1 (Ang1), angiopoietin 2 (Ang2), angiopoietin 3 (Ang3) and/or angiopoietin 4 (Ang4). The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Tie2 biological activities including angiogenesis.

Abstract: The subject matter of the present invention relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compound to interact with netrin-1 receptor and/or to inhibit the dimerization of the intracellular domain of the netrin-1 receptor expressed in tumor cells. The invention also relates to a method for predicting the presence of metastatic or aggressive cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of netrin-1. The invention further comprises kits and compounds as a medicament for the treatment of cancer such as metastatic breast cancer, related to the overexpression of netrin-1 by the tumor cells.

Abstract: The present invention relates to the field of medicine. More particularly, the present disclosure relates to combinations of an antibody that binds colony-stimulating factor 1 receptor (CSF-IR) and an antibody that binds human programmed cell death I ligand 1 (PD-L1) and to methods of using the combination to treat cancer, and in particular solid tumors with macrophage infiltration.

Abstract: Provided herein is are methods of treating Chronic Obstructive Pulmonary Disease (COPD) in a patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.

Abstract: The present disclosure relates to anti-SSEA4 antibodies and bindings fragments thereof comprising specific complementarity determining regions capable of high affinity binding to SSEA4 molecules and SSEA4-associated expressing tumor cells, such as breast cancer, pancreatic cancer, and renal cancer cells. The anti-SSEA4 antibodies and binding fragments induce ADCC or CDC effects in the targeted tumor cells and inhibit and/or reduce the cancer/tumor proliferation. The present disclosure also provides anti-SSEA4 antibodies and binding fragments thereof as a pharmaceutical composition for treating cancer. In addition, the anti-SSEA4 antibodies and binding fragments are useful in the diagnosis of cancers.

Abstract: The present invention relates to trispecific antibodies binding to HER2 and a blood-brain barrier receptor (BBB-R), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).

Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, a bispecific T-Cell engager recombinant polypeptide comprising an antibody, fragment thereof, or single chain variable fragment that binds to CD3 of a T-cell antigen receptor and an antibody, fragment thereof, or single chain variable fragment that binds to Programmed Death Ligand 1 (PDL1) on a cancerous tumor cell to counteract the immune tolerance of cancer cells.

Abstract: The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.

Abstract: The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.

Abstract: To provide a cellulose derivative excellent in thermoplasticity, water resistance and strength (elastic modulus, impact strength), a cellulose derivative, which is obtained by introducing a short-chain organic group (acetyl group), a medium-chain organic group having 3 to 5 carbon atoms and a long-chain organic group having 6 to 30 carbon atoms at the following substitution degrees DSs into a cellulose, is used: Short-chain organic group: 0.7?DSSH?1.5; Medium-chain organic group: 0.5?DSME?2.0; Long-chain organic group: 0.1?DSLO<0.5; and 2.4?DSSH+DSME+DSLO?3.

Abstract: The invention relates to the technology for the production of celluloses having improved properties and increased reactivity, and can be used in their chemical processing, including finished batches for the production of nitrocellulose and other products. A method for improving the quality and reactivity of cellulose comprises the following steps: impregnating and hydrolyzing the cellulose in a hydrolysis solution, filtering it from the hydrolysis solution, washing it with squeezing and drying. Moreover, the stages of impregnation and hydrolysis of cellulose in hydrolysis solution, filtration from hydrolysis solution, washing, squeezing and drying are carried out with simultaneous thermovacuum-impulse action by cycles, each of which includes the heating of cellulose to a temperature of not more than 115° C., high-speed impulse action of vacuum for time of less than 10 seconds, followed by exposure of the cellulose under vacuum and vacuum relief.

Abstract: The present invention relates to a method for manufacturing nanocellulose comprising the steps of: a) providing a cellulose-containing material wherein the cellulose-containing material contains less than 20 wt. % water, b) contacting the cellulose-containing material with oxalic acid dihydrate, and heating above the melting point of the oxalic acid dihydrate, to obtain cellulose oxalates, c) washing the mixture, d) preparing a suspension comprising the washed material from step c) and e) recovering nanocellulose from the suspension. The present invention relates also to a method of manufacturing nanocellulose intermediate which comprises the above described steps a)-c). The methods disclosed in the present invention are quick, simple, and direct. Pulp can be used as raw material. A considerable amount of free carboxyl groups are introduced. A high yield can be obtained. The methods are inexpensive.

Abstract: Provided herein are a glucan kinase polypeptide, an isolated polynucleotide, and a method for processing starch. The glucan kinase polypeptide comprises an isolated polypeptide including a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO:22, fragments thereof, variants thereof, and combinations thereof. The isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 21, a fragment thereof, a variant thereof, and a combination thereof. The method for processing starch comprises providing a glucan dikinase; exposing a starch to the glucan dikinase; and collecting the starch that has been exposed to the glucan dikinase.

Abstract: A method for preparing high transparent low acyl gellan gum from fermentation broth is provided, in which two-stage filtrations are carried out on deacylated gellan gum fermentation broth by using diatomite and/or perlite with different particle sizes as filter aid and filter media. The obtained product has high gel transparency and low content of metal ions. The method also has the advantages of simple pretreatment of fermentation broth, high impurities removal efficiency, simple operation, and easy to be industrialized.

Abstract: A hydrocolloid or aqueous solution comprising a poly alpha-1,3-glucan ether compound is disclosed having a viscosity of at least about 10 centipoise (cPs). The poly alpha-1,3-glucan ether compound in these compositions has a degree of substitution of about 0.05 to about 3.0. Also disclosed is a method for increasing the viscosity of a hydrocolloid or aqueous composition using a poly alpha-1,3-glucan ether compound.

Abstract: Provided herein are di-functionalized hyaluronic acids, such as molecules including (or that have been functionalized at) a thiol and azide side chain. Also, provided herein are hydrogels of these di-functionalized hyaluronic acids and methods of using these compounds to promote cell (e.g., neuronal cell) growth and development. In some aspects, the present disclosure also provides methods of treating injuries, including brain injuries such as stroke through the use of hydrogels of the compounds described herein and stem cells.

Abstract: Polar silane linkers are provided that attach to resins to form silane-functionalized resins. The functionalized resins can be bound to hydroxyl groups on the surface of silica particles to improve the dispersibility of the silica particles in rubber mixtures. Further disclosed are synthetic routes to provide the silane-functionalized resins, as well as various uses and end products that benefit from the unexpected properties of the silane-functionalized resins. Silane-functionalized resins impart remarkable properties on various rubber compositions, such as tires, belts, hoses, brakes, and the like. Automobile tires incorporating the silane-functionalized resins are shown to possess excellent results in balancing the properties of rolling resistance, tire wear, and wet braking performance.

Abstract: Polar silane linkers are provided that attach to resins to form silane-functionalized resins. The functionalized resins can be bound to hydroxyl groups on the surface of silica particles to improve the dispersibility of the silica particles in rubber mixtures. Further disclosed are synthetic routes to provide the silane-functionalized resins, as well as various uses and end products that benefit from the unexpected properties of the silane-functionalized resins. Silane-functionalized resins impart remarkable properties on various rubber compositions, such as tires, belts, hoses, brakes, and the like. Automobile tires incorporating the silane-functionalized resins are shown to possess excellent results in balancing the properties of rolling resistance, tire wear, and wet braking performance.

Abstract: Process for the preparation of (co) polymers of conjugated dienes comprising polymerizing at least one conjugated diene in the presence of a catalytic system comprising at least one vanadium bis-imine complex having the general formula (I): wherein: m is 0 or 1; Z represents a —CR5R6 group wherein R5 and R6, equal to or different from each other, represent a hydrogen atom; or a C1-C20 alkyl group, preferably C1-C15, linear or branched; or a bivalent aromatic group optionally substituted; R1 and R2 equal to or different from each other, represent a hydrogen atom; or they are selected from C1-C20 alkyl groups, preferably C1-C15, linear or branched, optionally halogenated, cycloalkyl groups optionally substituted; or R1 and R2, may be optionally bound each other so as to form, together with the other atoms which they are bound to, a cycle containing from 4 to 6 carbon atoms, saturated, unsaturated, or aromatic, optionally substituted by C1-C20 alkyl groups, preferably C1-C15, linear or branched, said cycle optio

Abstract: A method for producing polyisoprene comprising: polymerizing isoprene by using an isoprene-containing composition containing isoprene and an oxygen-containing neutral compound, and a polymerization catalyst composition containing a rare earth element compound and an organometallic compound, wherein: —a compounding amount of the organometallic compound is 0.6 to 3.0 parts by mass per 100 parts by mass of the isoprene-containing composition.

Abstract: A polymer obtained by a solution polymerization process comprising within a range from 0.5 to 20 wt % of cyclic olefin derived units, within a range from 0 wt % to 15 wt % C4 to C12 ?-olefin derived units, the remainder being ethylene derived units; and having a Mw/Mn of less than 2.5; a weight average molecular weight (Mw) within a range from 80,000 to 300,000 g/mole; and a g? value of greater than 0.95. The polymer may be formed in a solution polymerization process comprising combining in a solution cyclic olefins, ethylene, hydrogen and optionally C4 to C12 ?-olefins with a single-site catalyst to form the polymer, wherein the single-site catalyst is most preferably selected from unsymmetrical Group 4 bis-bridged cyclopentadienyl metallocenes.